Catalyst Pharmaceutical Partners (CPRX) PT Raised to $6.50 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Rating Summary:
7 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
7 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
Roth Capital analyst Scott Henry raised the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $6.50 (from $6.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nextpower (NXT) PT Raised to $158 at GLJ Research
- trivago N.V. (TRVG) PT Lowered to $4.80 at UBS
- Tempus AI Inc (TEM) PT Raised to $92 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
